Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

MannKind is a biopharmaceutical company with a positive outlook due to the potential growth of its royalty and collaboration revenue streams, including the pursuit of Tyvaso DPI for interstitial pulmonary fibrosis (IPF). Additionally, the company's MNKD-201 nintedanib DPI program in IPF and MNKD-1501 ralinepag DPI program for pulmonary arterial hypertension (PAH) provide additional upside potential. Despite reporting lighter-than-expected earnings, the company has a strong balance sheet and multiple upcoming catalysts, making it a favorable investment opportunity with a price target of $10-11 based on a discounted cash flow model. However, risks include commercial execution, clinical trials, and regulatory risks, as well as the possibility of a partner controlling commercialization of key products.

Bears say

MannKind is a biopharmaceutical company with three commercially available products, but our analysis shows potential challenges for sustained growth. Though the company has a promising catalyst in the upcoming FDA decision on the 7/26/26 FUROSCIX ReadyFlow autoinjector, the shift to this format may not be as smooth as expected, with potential cost and training hurdles. This, as well as the seasonal and transitional nature of FUROSCIX sales, indicate potential difficulties in driving long-term revenue growth.

MannKind (MNKD) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 7 analysts, MannKind (MNKD) has a Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.